10341-87-4

Upstream product

• 2404-87-7 3-phenylthiophene 
• 872-31-1 3-Bromothiophene 
• 100-59-4 phenylmagnesium chloride 
• 7732-18-5 water 
• 108-86-1 bromobenzene 
• 2288-18-8 2-phenyl-1,3-butadiene 
• 6051-52-1 2-phenylbut-3-en-2-ol 
• 98-80-6 phenylboronic acid 
• 259148-90-8 2-[chloro(diisopropyl)silyl]-3-phenylthiophene 
• 259148-94-2 2-[benzyloxy(diisopropyl)silyl]-3-phenylthiophene 

Downstream Products

• 19163-24-7 5-phenyl-2-thiophenecarboxylic acid 
• 259148-90-8 2-[chloro(diisopropyl)silyl]-3-phenylthiophene 
• 914360-68-2 9-(3-phenylthiophen-2-yl)fluoren-9-ol 
• 914360-72-8 2-bromo-9-(3-phenyl-thiophen-2-yl)-9H-fluoren-9-ol 
• 16939-12-1 2,3-diphenylthiophene 
• 58267-82-6 methyl 2-(3-phenylthiophen-2-yl)benzoate 

Relevant academic research and scientific papers

2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(amino-oxo-aryl-λ6- sulfanylidene)acetamide compounds (referred to herein as ANASIA compounds) that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.

Cap-dependent endonuclease inhibitors

The present invention provides a compound of formula (I) for inhibiting influenza virus replication. A pharmaceutically acceptable salt, metabolite, or prodrug thereof. The compounds can be used for preparing medicaments for treating influenza. The invention further discloses a method and for preparing the same, and a composition comprising the compound and a pharmaceutically acceptable carrier.

Redox-Divergent Construction of (Dihydro)thiophenes with DMSO

Thiophene-based rings are one of the most widely used building blocks for the synthesis of sulfur-containing molecules. Inspired by the redox diversity of these features in nature, we demonstrate herein a redox-divergent construction of dihydrothiophenes, thiophenes, and bromothiophenes from the respective readily available allylic alcohols, dimethyl sulfoxide (DMSO), and HBr. The redox-divergent selectivity could be manipulated mainly by controlling the dosage of DMSO and HBr. Mechanistic studies suggest that DMSO simultaneously acts as an oxidant and a sulfur donor. The synthetic potentials of the products as platform molecules were also demonstrated by various derivatizations, including the preparation of bioactive and functional molecules.

INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF

Disclosed are a compound as shown in formula (I) as an influenza virus replication inhibitor and a preparation method therefor, a pharmaceutical composition comprising the compound and the use of the compound and pharmaceutical composition thereof in the treatment of influenza.

Biological Evaluation and X-ray Co-crystal Structures of Cyclohexylpyrrolidine Ligands for Trypanothione Reductase, an Enzyme from the Redox Metabolism of Trypanosoma

The tropical diseases human African trypanosomiasis, Chagas disease, and the various forms of leishmaniasis are caused by parasites of the family of trypanosomatids. These protozoa possess a unique redox metabolism based on trypanothione and trypanothione reductase (TR), making TR a promising drug target. We report the optimization of properties and potency of cyclohexylpyrrolidine inhibitors of TR by structure-based design. The best inhibitors were freely soluble and showed competitive inhibition constants (Ki) against Trypanosoma (T.) brucei TR and T. cruzi TR and in vitro activities (half-maximal inhibitory concentration, IC50) against these parasites in the low micromolar range, with high selectivity against human glutathione reductase. X-ray co-crystal structures confirmed the binding of the ligands to the hydrophobic wall of the “mepacrine binding site” with the new, solubility-providing vectors oriented toward the surface of the large active site.

Synthesis, SAR study, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase (FAAH) inhibitors

A series of piperazine ureas was designed, synthesized, and evaluated for their potential as novel orally available fatty acid amide hydrolase (FAAH) inhibitors that are therapeutically effective against pain. We carried out an optimization study of the l

HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE

The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

Azulene-containing organic chromophores with tunable near-IR absorption in the range of 0.6 to 1.7 μm

Near-infrared (NIR) absorption in the range of 0.75-2.5 μm is in great demand for a variety of applications but currently the majority of commercial NIR devices are based on inorganic materials due to the limited number of organic materials that are active in this range. Here we present the preparation and optical studies of a new series of stable azulene-containing NIR chromophores whose absorption can be tuned in the range of 0.6-1.7 μm. DFT calculation revealed that the protonation-induced low excitation gap was attributable to the substantial intramolecular charge transfer. The Royal Society of Chemistry 2012.

Rewiring chemistry: Algorithmic discovery and experimental validation of one-pot reactions in the network of organic chemistry

Computational algorithms are used to identify sequences of reactions that can be performed in one pot. These predictions are based on over 86 000 chemical criteria by which the putative sequences are evaluated. The "raw" algorithmic output is then validated experimentally by performing multiple two-, three-, and even four-step sequences. These sequences "rewire" synthetic pathways around popular and/or important small molecules. Copyright

AMIDE COMPOUND

There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I0): wherein Z is oxygen or sulfur; R1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R3 is a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, -CO-, etc.; and R4 is a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.